Approval belongs to a product
In the September 2026 record, compounded semaglutide had no FDA approval. These drugs reached sale without the agency first checking their quality, safety or how well they worked.
The September 2026 search found no generic semaglutide with FDA approval for U.S. sale. A tentative approval was on record, but did not allow sales.
The November 3, 2026 check found no generic of semaglutide or tirzepatide with FDA approval allowing U.S. sales.
A drug made by a pharmacy is a different kind of product. Ask which kind the service means. Do that before checking prices as though the drugs were the same.
The FDA guidance checked in September 2026 rejected two claims about compounded drugs. They cannot be called approved generics. It is also misleading to say studies prove the compounded drug gives the results of an approved medicine.
Registration is a different claim
The federal rule checked in September 2026 says a registration or drug listing does not grant FDA approval. It does not prove the drug can be sold lawfully either.
Ask exactly what a badge or registration statement refers to. Request the underlying record and its meaning. Ask what drug is meant and which rule applies to it. A badge alone does not answer either question.
Ask for a prescription process and a pharmacy name
The September 2026 law review found that a prescription drug cannot lawfully be dispensed without a valid prescription. The FDA also flagged sites that skip that step.
FDA reports checked in September 2026 described fake compounded semaglutide labels. A pharmacy name could be invented. Or a real pharmacy could be named on a drug it never prepared.
Ask for the pharmacy’s actual name and check the state license record using the FDA’s lookup links. When a name fails to match, ask both the service and pharmacy to account for that gap. A clean-looking label does not complete that check.
Ask who answers questions about the prescription. Keep a way to contact the dispensing pharmacy with the product details. A billing contact and a medicine-question contact can serve different purposes; ask which is which.
A low price needs context
The FDA’s online-pharmacy checklist includes implausibly deep discounts among its caution signs. A low amount alone does not establish a problem, because legitimate cash offers can sit below list prices.
Read the price with the other checks. Ask whether it is medicine-only, introductory, tied to advance payment or attached to a given product. Do not let the size of the discount settle the product question or the prescription question.
The FDA position checked in September 2026 treated semaglutide sodium and semaglutide acetate as different active ingredients from those in approved drugs. These names describe changed chemical forms of semaglutide, called salts. The FDA knew of no lawful basis to compound with those salts.
If sodium or acetate appears after semaglutide in the planned product description, ask the pharmacist about that exact name and discuss it with whoever writes the prescription. Ask the pharmacist to spell out the exact name and form of the ingredient. The answer needs to match the drug being discussed, not just the short name in an ad. Keep the wording for the next medical conversation. A new name for the same uncertain item does not settle the concern.